LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets

Iksuda also gains access to LegoChem Biosciences’ new payload, supplementing the tumour-activated payloads accessed in 2020

Newcastle, UK, 22 June, 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.